|
|
Post by rfogel on Dec 17, 2019 10:15:22 GMT -5
I'm surprised Mannkind hasn't issued some sort of press release announcing that Brazil pricing has been determined and/or explaining afrezza's disappearance from the revised Anvisa list.
|
|
|
|
Post by agedhippie on Dec 17, 2019 11:13:55 GMT -5
I'm surprised Mannkind hasn't issued some sort of press release announcing that Brazil pricing has been determined and/or explaining afrezza's disappearance from the revised Anvisa list. They are probably waiting for it to resolve. BIOMM have not issued a PR either. |
|
|
|
Post by matt on Dec 17, 2019 11:40:30 GMT -5
I'm surprised Mannkind hasn't issued some sort of press release announcing that Brazil pricing has been determined and/or explaining afrezza's disappearance from the revised Anvisa list. They are probably waiting for it to resolve. BIOMM have not issued a PR either. Ultimately clerical errors (which I suspect is the case here with the disappearance of Afrezza in the V2 spreadsheet) are the responsibility of the marketing partner to handle. However, CMED has made their determination of pricing, consistent with government guidelines, so the numbers are unlikely to change.
Given the very modest prices awarded by CMED, is that something either company (MNKD or Biomm) wants to PR? SEC rules certainly don't require it.
|
|
|
|
Post by agedhippie on Dec 17, 2019 12:26:16 GMT -5
They are probably waiting for it to resolve. BIOMM have not issued a PR either. Ultimately clerical errors (which I suspect is the case here with the disappearance of Afrezza in the V2 spreadsheet) are the responsibility of the marketing partner to handle. However, CMED has made their determination of pricing, consistent with government guidelines, so the numbers are unlikely to change.
Given the very modest prices awarded by CMED, is that something either company (MNKD or Biomm) wants to PR? SEC rules certainly don't require it.
I suspect BIOMM will do a PR because they are trying to promote themselves as having a portfolio of drugs. Interestingly one of the BIOMM board members is an ex-CEO of ANVISA. |
|
|
|
Post by rfogel on Dec 17, 2019 13:26:39 GMT -5
They are probably waiting for it to resolve. BIOMM have not issued a PR either. Ultimately clerical errors (which I suspect is the case here with the disappearance of Afrezza in the V2 spreadsheet) are the responsibility of the marketing partner to handle. However, CMED has made their determination of pricing, consistent with government guidelines, so the numbers are unlikely to change.
Given the very modest prices awarded by CMED, is that something either company (MNKD or Biomm) wants to PR? SEC rules certainly don't require it.
Well, although they may not want to brag about the pricing, it still means they're now officially allowed to sell the drug. I'm having a bit of trouble buying the clerical error explanation. I mean, for the whole afrezza section to totally disappear just seems more organized than error. |
|
|
|
Post by matt on Dec 17, 2019 17:58:02 GMT -5
Well, although they may not want to brag about the pricing, it still means they're now officially allowed to sell the drug. I'm having a bit of trouble buying the clerical error explanation. I mean, for the whole afrezza section to totally disappear just seems more organized than error. It depends what the error was. If ANVISA started over with the spreadsheet from November (which did not contain the Afrezza data either) then it is entirely plausible that they fixed some problems but forgot to include the new products for December in Version 2. Given that this is a 27,000 row spreadsheet it would not be surprising that missing a few rows went unnoticed. At any rate, Biomm is now allowed to see the drug they have on hand and can communicate the pricing to retail pharmacies. It will be interesting to see if they launch it any faster than Sanofi or MKND did in the US. If they burn through all $700,000 of the initial product and have to order more before the end of Q1, that would be a good indicator. |
|
|
|
Post by robbmo on Dec 17, 2019 18:41:11 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us.
|
|
|
|
Post by longliner on Dec 17, 2019 20:06:57 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us. Good God they could raise this much on proboards. It really is time to quit spinning our wheels! Mike, so we got burned in the "deep end" once, it's time to swim buddy!!!! |
|
|
|
Post by rfogel on Dec 18, 2019 0:14:28 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us. Where did you see that? |
|
|
|
Post by rfogel on Dec 18, 2019 0:16:07 GMT -5
Well, although they may not want to brag about the pricing, it still means they're now officially allowed to sell the drug. I'm having a bit of trouble buying the clerical error explanation. I mean, for the whole afrezza section to totally disappear just seems more organized than error. It depends what the error was. If ANVISA started over with the spreadsheet from November (which did not contain the Afrezza data either) then it is entirely plausible that they fixed some problems but forgot to include the new products for December in Version 2. Given that this is a 27,000 row spreadsheet it would not be surprising that missing a few rows went unnoticed. At any rate, Biomm is now allowed to see the drug they have on hand and can communicate the pricing to retail pharmacies. It will be interesting to see if they launch it any faster than Sanofi or MKND did in the US. If they burn through all $700,000 of the initial product and have to order more before the end of Q1, that would be a good indicator. Yes, but it's still suspicious that those few rows managed to wipe out all of the afrezza rows. |
|
|
|
Post by robbmo on Dec 18, 2019 10:11:33 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us. Where did you see that? On their website. |
|
|
|
Post by agedhippie on Dec 18, 2019 12:28:59 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us. I think that's the wrong tense. I think they have raised it. The regional development bank bought into them (conveniently the CEO of the bank is on BIOMM's board). This is about their insulin plant, they need the money for it to go live now they have built it. |
|
|
|
Post by robbmo on Dec 18, 2019 15:49:33 GMT -5
Biomm is raising US$20M dollars. I hope that bodes well for us. I think that's the wrong tense. I think they have raised it. The regional development bank bought into them (conveniently the CEO of the bank is on BIOMM's board). This is about their insulin plant, they need the money for it to go live now they have built it. What I read, granted in Portuguese, is it opens on 12/19/2019. |
|
